Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-22,838
Closed -$1.34M 281
2021
Q4
$1.34M Sell
22,838
-28,552
-56% -$1.73M 0.22% 225
2021
Q3
$3.12M Buy
51,390
+23,258
+83% +$1.36M 0.53% 44
2021
Q2
$1.69M Buy
+28,132
New +$1.41M 0.26% 176
2020
Q3
Sell
-54,558
Closed -$2.47M 276
2020
Q2
$2.47M Buy
+54,558
New +$2.79M 0.55% 49
2019
Q3
Sell
-18,326
Closed -$861K 237
2019
Q2
$861K Sell
18,326
-10,529
-36% -$445K 0.21% 206
2019
Q1
$1.01M Sell
28,855
-31,880
-52% -$1.25M 0.25% 186
2018
Q4
$2.27M Buy
+60,735
New +$2.37M 0.62% 36

Other funds holding ATEX

EAM Investors's ATEX Position: Q1 2022 in Review

EAM Investors sold out of Anterix (ATEX) in Q1 2022, closing a stake of 22,838 shares — an estimated $1.34M sold.

EAM Investors first reported a position in ATEX in Q4 2018 and held it in 7 quarters. The position peaked at $3.12M in Q3 2021. 109 funds tracked by Wall St. Rank hold ATEX as of Q1 2022.

  • EAM Investors reported no remaining Anterix position as of Q1 2022 after selling out during the quarter.
  • EAM Investors sold 22,838 Anterix shares in Q1 2022, an estimated $1.34M.
  • EAM Investors first reported a position in Anterix in Q4 2018 and held it in 7 quarters.
  • EAM Investors's Anterix position peaked at $3.12M in Q3 2021.
  • 109 funds tracked by Wall St. Rank held Anterix as of Q1 2022.

Based on EAM Investors's 13F filing for Q1 2022, filed 13 May 2022.